aminolevulinic acid
aminolevulinic acid: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Biofrontera Inc. (BFRI) | Phase 3 |
FDA Decisions
Frequently asked questions
Who is developing aminolevulinic acid?
aminolevulinic acid is being developed by Biofrontera Inc..
What is aminolevulinic acid's latest FDA decision?
The most recent tracked FDA decision for aminolevulinic acid is Approval for 1. INDICATIONS AND USAGE AMELUZ, in combination with photodynamic therapy (PDT) using BF-RhodoLED ® or RhodoLED ® XL lamp, a narrowband, red light illumination source, is indicated for lesion-directed and field-directed treatment of actinic keratoses (AKs) of mild-to-moderate severity on the face and scalp. AMELUZ, a porphyrin precursor, in combination with photodynamic therapy using BF-RhodoLED or RhodoLED XL lamp, is indicated for the lesion-directed and field-directed treatment of actinic ker, dated May 10, 2016.
Get deeper analysis on aminolevulinic acid
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis